Anteris Technologies Ltd
ASX:AVR
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
9.91
23.55
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one AVR stock under the Base Case scenario is 0.77 AUD. Compared to the current market price of 9.91 AUD, Anteris Technologies Ltd is Overvalued by 92%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Anteris Technologies Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for AVR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Anteris Technologies Ltd
Balance Sheet Decomposition
Anteris Technologies Ltd
Current Assets | 16.9m |
Cash & Short-Term Investments | 10.8m |
Receivables | 1.7m |
Other Current Assets | 4.4m |
Non-Current Assets | 9.6m |
PP&E | 8.5m |
Intangibles | 1.1m |
Other Non-Current Assets | -10 |
Current Liabilities | 17.7m |
Accounts Payable | 13.9m |
Other Current Liabilities | 3.8m |
Non-Current Liabilities | 3.1m |
Long-Term Debt | 1.7m |
Other Non-Current Liabilities | 1.5m |
Earnings Waterfall
Anteris Technologies Ltd
Revenue
|
7.1m
AUD
|
Cost of Revenue
|
-2.3m
AUD
|
Gross Profit
|
4.9m
AUD
|
Operating Expenses
|
-96.2m
AUD
|
Operating Income
|
-91.4m
AUD
|
Other Expenses
|
3.5m
AUD
|
Net Income
|
-87.9m
AUD
|
Free Cash Flow Analysis
Anteris Technologies Ltd
AUD | |
Free Cash Flow | AUD |
AVR Profitability Score
Profitability Due Diligence
Anteris Technologies Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Anteris Technologies Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
AVR Solvency Score
Solvency Due Diligence
Anteris Technologies Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Anteris Technologies Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AVR Price Targets Summary
Anteris Technologies Ltd
According to Wall Street analysts, the average 1-year price target for AVR is 26.52 AUD with a low forecast of 26.26 AUD and a high forecast of 27.3 AUD.
Dividends
Current shareholder yield for AVR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
AVR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Anteris Technologies Ltd. is a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. The company is headquartered in Toowong, Queensland. The company went IPO on 2004-03-24. The firm is engaged in delivering solutions that help healthcare professionals. The firm operates through two segments: operations and projects. Operation segment provides Bio implant ADAPT operations inclusive of manufacturing and sales. Project segment includes Transcatheter Aortic Valve Replacement (TAVR), which is developed using ADAPT 3D single-piece technology and other development projects across the Company. The company offers two products, ADAPT and DurAVR. ADAPT technology is a BioScaffold, which is a tissue technology platform that demonstrates zero calcification. xenograft tissue into a pure collagen scaffold with optimized strength and pliability, biocompatibility and unparalleled durability. DurAVR heart valve Is focused on delivering a functional cure in the treatment of Severe Aortic Stenosis.
Contact
IPO
Employees
Officers
The intrinsic value of one AVR stock under the Base Case scenario is 0.77 AUD.
Compared to the current market price of 9.91 AUD, Anteris Technologies Ltd is Overvalued by 92%.